• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Complement mutation linked to poor response to eculizumab

byAkira ShishidoandXu Gao
February 14, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: CC/Wiki/Uthman

1. Paroxysmal nocturnal hemoglobinuria (PNH) patients with poor response to eculizumab were found to have a mutation in complement protein C5. 

2. When tested in vitro, the mutant C5 protein did not bind eculizumab, suggesting that the mechanism for resistance in these patients is protein-drug binding disruption caused by the C5 mutation. 

Evidence Rating Level: 2 (Good)            

Study Rundown: PNH causes intravascular hemolysis and stems from a deficiency in complement regulatory proteins.  The monoclonal antibody eculizumab targets complement protein C5 and inhibits the formation of the cytolytic pore C5b-9 thereby greatly reducing the complement-mediated hemolysis seen in PNH patients.  While more than 99% of patients have good response to eculizumab, a specific subset of patients in Japan do not.  The authors of this study sought to identify the cause of this.  They identified a mutation in the C5 gene that appears to disrupt the binding of eculizumab to C5 and therefore its ability to inhibit hemolysis in patients with PNH.  The in vitro binding studies suggested that the mechanism of resistance among these patients is due to a change in the C5 binding site of eculizumab.  The authors then demonstrated the prevalence of these mutations in sample pools in different populations, but they were relatively small sample sizes.  This study provides solid evidence clarifying the mechanism for poor response to eculizumab in patients with PNH.

Click to read the study in NEJM

Relevant Reading: Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial

RELATED REPORTS

Mitapivat efficacious in treating pyruvate kinase deficiency

Detection of pathogenic genetic variants in early-onset atrial fibrillation

#VisualAbstract: Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

Study Author, Dr. Jun-ichi Nishimura, MD, PhD, talks to 2 Minute Medicine: Assistant Professor, Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

“Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement–mediated hemolysis associated with PNH. We identified a C5 polymorphism (c.2654G→A) in Japanese patients with PNH that prevents binding and blockade by eculizumab, while retaining the functional capacity of the mutant C5 to cause hemolysis.  Therefore, the polymorphism in the target protein might be important to consider in patients with a poor response to the antibody-based treatments for various diseases.”

In-Depth [genetic analysis study]: This study aimed to identify the molecular basis for the poor response to eculizumab found in a particular subset of Japanese PNH patients.  The authors collected blood samples from a total of 12 patients (11 Japanese and 1 Argentinian of Asian ancestry) who had poor response to eculizumab and 8 controls (7 patients with good response to eculizumab and 1 healthy patient).  They sequenced the C5 gene for all patients enrolled in the study and identified a missense mutation in exon 21 (c.2654G->A) which produced the polymorphis p.Arg885His.  This same mutation was identified in all 11 Japanese patients who had poor response to eculizumab, and in none of the controls. The Argentinian patient had a different mutation: c.2653->T that produced p.Arg885Cys.  An in vitro study was then performed that demonstrated that eculizumab did not bind the mutant C5 protein.  However, the monoclonal antibody N19-8, that binds a different site on C5, bound both.

More from this author: Pneumocystis linked to sudden infant deaths, Continuous infusion of beta-lactams may be superior to bolus therapy, Novel antiviral drug reduces influenza viral load, Three months of antibiotics appear to effectively treat early-onset spinal implant infections

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: Eculizumabgenetic mutationhemolytic anemiaParoxysmal nocturnal hemoglobinuria
Previous Post

Screening mammography may not decrease overall mortality in women ages 40-59

Next Post

Initial trial of conservative management of splenic injury [Pediatrics Classics Series]

RelatedReports

Complement mutation linked to poor response to eculizumab
Chronic Disease

Mitapivat efficacious in treating pyruvate kinase deficiency

May 10, 2022
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Detection of pathogenic genetic variants in early-onset atrial fibrillation

September 16, 2021
#VisualAbstract: ChAdOx1-nCoV-19 vaccine maintains efficacy despite a longer prime-boost interval
StudyGraphics

#VisualAbstract: Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

March 25, 2021
Study explores effects of daily iron supplementation in 2- to 5-year-olds
All Specialties

Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

March 18, 2021
Next Post

Initial trial of conservative management of splenic injury [Pediatrics Classics Series]

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

Teledermatology may be reliable in triaging inpatient dermatology consultations

Teledermatology may be reliable in triaging inpatient dermatology consultations

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.